NASDAQ:LEXX Lexaria Bioscience (LEXX) Stock Price, News & Analysis $0.83 -0.01 (-1.07%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$0.83 0.00 (-0.48%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lexaria Bioscience Stock (NASDAQ:LEXX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lexaria Bioscience alerts:Sign Up Key Stats Today's Range$0.82▼$0.8550-Day Range$0.81▼$1.0552-Week Range$0.79▼$4.38Volume117,397 shsAverage Volume205,362 shsMarket Capitalization$16.23 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingBuy Company Overview Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada. Read More Lexaria Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreLEXX MarketRank™: Lexaria Bioscience scored higher than 53% of companies evaluated by MarketBeat, and ranked 423rd out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingLexaria Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageLexaria Bioscience has only been the subject of 1 research reports in the past 90 days.Read more about Lexaria Bioscience's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Lexaria Bioscience are expected to grow in the coming year, from ($0.59) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lexaria Bioscience is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lexaria Bioscience is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLexaria Bioscience has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.92% of the float of Lexaria Bioscience has been sold short.Short Interest Ratio / Days to CoverLexaria Bioscience has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Lexaria Bioscience has recently increased by 1.90%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLexaria Bioscience does not currently pay a dividend.Dividend GrowthLexaria Bioscience does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.92% of the float of Lexaria Bioscience has been sold short.Short Interest Ratio / Days to CoverLexaria Bioscience has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Lexaria Bioscience has recently increased by 1.90%, indicating that investor sentiment is decreasing. News and Social Media1.5 / 5News Sentiment-0.32 News SentimentLexaria Bioscience has a news sentiment score of -0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Lexaria Bioscience this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for LEXX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Lexaria Bioscience to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Lexaria Bioscience insiders have bought more of their company's stock than they have sold. Specifically, they have bought $49,063.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders26.40% of the stock of Lexaria Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.06% of the stock of Lexaria Bioscience is held by institutions.Read more about Lexaria Bioscience's insider trading history. Receive LEXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexaria Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address LEXX Stock News HeadlinesInsider Buying: Lexaria Bioscience Corp. (NASDAQ:LEXX) Director Buys 11,900 Shares of StockJuly 31, 2025 | insidertrades.comHC Wainwright Expects Lower Earnings for Lexaria BioscienceAugust 2, 2025 | americanbankingnews.comCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% worldwide. Now he’s applying the same expertise to the Bitcoin market. His system tracks 19 indicators to find quick Bitcoin profit opportunities.August 8 at 2:00 AM | Brownstone Research (Ad)LEXX: Third Quarter ResultsJuly 31, 2025 | finance.yahoo.comHC Wainwright Issues Pessimistic Forecast for Lexaria Bioscience (NASDAQ:LEXX) Stock PriceJuly 31, 2025 | americanbankingnews.comLEXX - Lexaria Bioscience Corp Dividends - MorningstarJuly 12, 2025 | morningstar.comMLexaria Bioscience announces completion of GLP-1-H25-5 studyJune 12, 2025 | finance.yahoo.comLexaria Bioscience Corp.: Lexaria Attending BIO International ConventionJune 5, 2025 | finanznachrichten.deSee More Headlines LEXX Stock Analysis - Frequently Asked Questions How have LEXX shares performed this year? Lexaria Bioscience's stock was trading at $2.10 on January 1st, 2025. Since then, LEXX shares have decreased by 60.5% and is now trading at $0.83. How were Lexaria Bioscience's earnings last quarter? Lexaria Bioscience Corp. (NASDAQ:LEXX) released its earnings results on Monday, July, 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.06. The business had revenue of $0.17 million for the quarter, compared to analysts' expectations of $0.17 million. Lexaria Bioscience had a negative net margin of 1,849.19% and a negative trailing twelve-month return on equity of 157.22%. How do I buy shares of Lexaria Bioscience? Shares of LEXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lexaria Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lexaria Bioscience investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and Builders FirstSource (BLDR). Company Calendar Last Earnings7/14/2025Today8/08/2025Fiscal Year End8/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LEXX CIK1348362 Webwww.lexariabioscience.com Phone(250) 765-6424FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Price Target for Lexaria Bioscience$4.00 High Price Target$4.00 Low Price Target$4.00 Potential Upside/Downside+381.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($0.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.80 million Net Margins-1,849.19% Pretax Margin-1,850.97% Return on Equity-157.22% Return on Assets-133.69% Debt Debt-to-Equity RatioN/A Current Ratio3.90 Quick Ratio3.90 Sales & Book Value Annual Sales$460 thousand Price / Sales35.29 Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book1.73Miscellaneous Outstanding Shares19,560,000Free Float14,395,000Market Cap$16.23 million OptionableNot Optionable Beta0.79 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:LEXX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.